Advances in Dyslipidemia Management for Prevention of Atherosclerosis: PCSK9 Monoclonal Antibody Therapy and Beyond

Cardiovascular Diagnosis and Therapy - China
doi 10.21037/cdt.2017.03.02
Full Text
Abstract

Available in full text

Date
Authors
Publisher

AME Publishing Company

Related search

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease

2015English

Monoclonal Antibody Therapy

AAOHN Journal
1987English

Monoclonal Antibody Therapy for Non-Malignant Disease

Australian Prescriber
Pharmacology
2006English

Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials

Frontiers in Cardiovascular Medicine
Cardiovascular MedicineCardiology
2019English

Zebrafish Models for Dyslipidemia and Atherosclerosis Research

Frontiers in Endocrinology
EndocrinologyMetabolismDiabetes
2016English

Prevention of Stirring-Induced Microparticle Formation in Monoclonal Antibody Solutions

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2010English

PCSK9 Inhibition: The Way Forward in the Treatment of Dyslipidemia

BMC Medicine
Medicine
2015English

Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis

Journal of Atherosclerosis and Thrombosis
BiochemistryInternal MedicineCardiovascular MedicineCardiology
2012English

Contemporary Management of Carotid Bifurcation Atherosclerosis for Stroke Prevention: Management Options and Patient Selection

Perspectives in Vascular Surgery and Endovascular Therapy
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy